A Negative Molecular Test in a Patient With Classic Symptoms
A 28-year-old returns from a region with ongoing transmission of an arthropod-borne virus. Five days after symptom onset (fever, arthralgia, a faint maculopapular rash) a serum sample is tested by a laboratory-developed RT-PCR assay. The result is negative. The clinician calls the laboratory and asks whether the patient can be cleared, noting the patient is anxious and wants a definitive answer. The laboratory's assay validation data show a limit of detection of about 500 copies/mL in serum, with a published note that viremia for this agent typically peaks around days 0-3 and is often below the limit of detection by day 5. The laboratory also offers IgM serology, which has cross-reactivity with related flaviviruses and can be confounded by prior vaccination or infection. No convalescent sample has been collected.
1. Explain why the negative PCR does not exclude infection and what the timing implies about test selection.
Read the worked answer
A negative result must be interpreted against the pretest probability and the test's performance in the sample actually obtained. This patient has a compatible exposure history, a compatible clinical syndrome, and a sample drawn at day 5-after the window in which viremia for this agent is typically detectable. The assay's limit of detection (~500 copies/mL) is also relevant: even if virus is present, the concentration may be below that threshold late in the course.
So the negative PCR is uninformative rather than reassuring. The correct interpretation is 'not detected at this time point,' not 'not infected.' The timing should have driven test selection: molecular testing is most useful early (days 0-3), while serology becomes the more useful tool later. The clinician should be told the result does not exclude the diagnosis and that further testing is needed.
2. Recommend a testing strategy to resolve the question, and address the limitations of the serologic option.
Read the worked answer
The appropriate strategy is paired serology: an acute serum collected now and a convalescent serum collected 2-4 weeks later, tested in parallel on the same platform. A fourfold rise in IgG titer between the two samples is the conventional evidence of recent infection; a single IgM is much weaker evidence.
The limitations must be stated explicitly. IgM can cross-react with related flaviviruses, so a positive result is not specific without confirmatory testing (e.g., plaque reduction neutralization) or a rising titer. Prior vaccination or prior infection can produce persistent or boosting IgM/IgG that confounds interpretation. A single acute sample that is IgM-negative also does not exclude infection if it was drawn too early for antibody to develop.
The practical answer to the clinician: do not clear the patient on the basis of the negative PCR. Collect the convalescent sample, counsel the patient about the uncertainty, and manage clinically. If the patient deteriorates, repeat molecular testing on the appropriate specimen type and consider additional agents in the differential.